Clinical guides, pricing breakdowns, and expert perspective on the medications and protocols changing how we age.
Why a coenzyme most people have never heard of has become the centerpiece of modern longevity protocols — and what the research actually shows.
The first head-to-head trial of the two leading GLP-1s, decoded in plain English.
A guide for the thousands of PA residents whose coverage ended January 1.
Bioavailability data, cost comparisons, and the honest pros and cons of each route.
A working framework for thinking about healthspan, biological age, and the interventions that move them.
A pricing breakdown of every legitimate path — compounded, branded, manufacturer direct, and insurance.
How telehealth, local clinics, and manufacturer programs compare — and the seven questions to ask any provider.
A close reading of the first head-to-head trial, beyond the headlines.
From Miami to Pensacola — the legitimate options, the legal framework, and the climate factor most articles ignore.
Texas-specific telehealth law, the post-shortage compounding shift, and what changed for patients in 2025.
Three molecules, three different paths to the same end state. Which actually raises NAD+ levels?
The 17,604-patient trial that changed how cardiologists think about GLP-1s.
Nausea, fatigue, GI changes — what causes each, what helps, and when to call your provider.
Why how you eat and move on a GLP-1 matters as much as the medication itself.